Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
112,508,491
-
Total 13F shares
-
50,178,896
-
Share change
-
+1,344,903
-
Total reported value
-
$464,099,871
-
Price per share
-
$9.25
-
Number of holders
-
35
-
Value change
-
+$5,440,465
-
Number of buys
-
18
-
Number of sells
-
9
Institutional Holders of NewAmsterdam Pharma Co N.V. - COMMON STOCK (NAMS) as of Q3 2023
As of 30 Sep 2023,
NewAmsterdam Pharma Co N.V. - COMMON STOCK (NAMS) was held by
35 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,178,896 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., Bain Capital Life Sciences Investors, LLC, RA CAPITAL MANAGEMENT, L.P., VIKING GLOBAL INVESTORS LP, Medicxi Ventures Management (Jersey) Ltd, BVF INC/IL, GMT CAPITAL CORP, ADAGE CAPITAL PARTNERS GP, L.L.C., MILLENNIUM MANAGEMENT LLC, and Eversept Partners, LP.
This page lists
35
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.